The tumor-targeting potential of the anti-HER2 nanobodies 5F7 and 2Rs15d labeled with 18F were assessed in a subcutaneous HER2-positive breast cancer murine model and in brain metastases [36,37]. Here, ERBB2 is linked to breast carcinoma.